Cure My Disease

Don't miss your cure!

 Log in / Sign up

Two blood markers put to the test for early liver cancer detection

NCT ID NCT03460080

Diagnosis Sponsor: Hanoi Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers at Hanoi Medical University are studying whether two blood markers, AFP-L3 and PIVKA-II, can accurately detect hepatocellular carcinoma, the most common form of liver cancer. The trial enrolls 200 adults, including people with liver cancer and people with benign liver tumors, and compares blood test results against standard imaging. All blood samples are collected before any treatment and tested at a single center to keep results consistent. The goal is to see if these markers could help doctors diagnose liver cancer earlier, when treatment is more likely to succeed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
blood tests for AFP-L3 and PIVKA-II
What this could lead to
If these markers prove accurate, doctors could detect liver cancer earlier with a simple blood test, when treatment works best.
What could go wrong
This is a single-center study of 200 people, so the results may not apply everywhere. The markers might not be sensitive enough to catch early tumors, and other conditions can affect their levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

200 people

The number who actually took part.

Started

Jan 2018

Finished

Dec 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The participants will be recruited through outpatient clinics and inpatient in Hanoi Medical University Hospital.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 85 * Receiving no treatment before diagnosis * Establishing Diagnosis according to thecriteria of Ministry of Public Health of Vietnam 2012. Exclusion Criteria: * Clinical data missing * Laboratory tests information missing * Serum samples doesn't qualified * Obstructive jaundice patients * Medical history of taking warfarin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatic hemangioma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma liver hemangioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

Contacts and locations

Locations

  • Hanoi Medical University

    Hanoi, Hanoi, 100000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.